R\5Z
MZDM8V+.-*UB"6'5M*8M)Y=M=&RDE>ZLKG;/^V)^S
M+HG[57P6UWX>73:?8>*K4_VW\/\ Q'?K*(M \5VD;K:R7,UM!> QE5N2UIRE"G4J>].]2G"6"QC:M.O' 8]WG5Q4B,?"/
MM*&882*56=J>.PM)*/-%3C&'@OQ>\;_ V\
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M[I0I8G!QAAXXN6M+$8>E##T:QPT)03=.5*K5Q$:L:L%1F^C%2C/&U
M\F^&;_ $G4O#^L^+O"%_\ 9=%UJ6P,NH77AZP\
M">%?$*1QSPVL,5\\@L8;IS;3JUSMC3\EO^"J?_)\/C7_ + WPZ_]1?2J_H7_
M &1?V._AU^R'X,OM!\*W5WXE\4^(Y;6Y\9>.=4M8;/4-=FLTD6SL[.PAEN(]
M'T.P,UP]EI:7=[*LMS/->7][,RR)^>W[:G_!-+XZ_M'?M&^(?B]X(\6?"72O
M#6K:?X4M+:Q\5:[XQL=<230M&LM.NVGMM(\!ZY8*DD]M(UL8]3D9XBC2K"Y*
M+W3<5G7#M2%2=3"X#$-UJT_X6'4WA:M7D;C"I[#VJGRRG3T'6[^#4O!OAGQ3X(TN.Y\.&
M*WGTG7M*TK7/ ^NZK=6K"2YL]1N(;ZXBMKRU/G1VJ7%L)?Z3O&/P^\+_ !%\
M!:Q\.?'6D6NO^&/$>AG0]%$+PRC9-;W%O/''=6-Y"8KFTNX8+J
M!XIXD9?P,^*?_!$WQ]'KUY/\%OBSX,O_ UU=#$8#"8;#XBA->[6I0P\4
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M6J8K"5L7AZ#Y*-;"X>JYSIO'GJTL37I*FJBA&ZE0A*E&#_$_Q9^,OQ:\3ZGKVE>)[N#6?!VB>(-,L=6MK.T@LKM=:\:ZQKEEK
M.L36.MI)=)#/9#3 L5K(\>MM?^[^S?
M\)D(_*_??:M_[BO4OC3_ ,$8=2WNH2[2FEB$E*,)N4HXK&PY(.G3C[.:/-".,HU
MI>WK5?:5?K=63<806(52%"@[R4\1/VBI\\4HO#8>I*I)3JOG_4_XZ_M!? OX
M#_!SPK'CS[WPCX[T:R\+QZ+'X3O_%MEXA6?0X);_3;V"*SGTA+:33VEF>'
M5KJV%[!'.+-+IX943\S? O[$7[ /[;>@:KXY_9Y\1>/OA-J-KJ^I6FI^#UU/
M2KZ72VAN8D&H7W@O7+SQ%JMGI&J1E+W0YM.\3V.GQQ7S6KVD$UJ=+T_]0==_
M9QL?C3^S1X:^!_[15KI&KZU:>%/#^G:UK/@V^NGAT[Q;X?TY=.MO%OA+4M3T
M?3+JWO R/=(EYHR6[)=W>EWEI>Z=+,EQ^+?C;_@B7\9;35I5^'/Q<^&.OZ$T
MTY@G\;1^*O".K0V_[MK:.6UT+0/&UGTO1<:BJ4*\'2^"/VA/A/
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M$K9;4R^IJY3J59U<-6IU^2_-*GAZV%S<<77I8=>S@O:?A/^QE_P $^?V/
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M#X>5*+>+Q*E*-&JVO92@W5'=>IRP_8/1]-@T;2-
M+T>UEGGMM*TZQTVWFN722YF@L;:*UBEN)(XXHY)Y(XE>5TBC1Y"S+&BD*-&B
MBL)SE4G.I.3E.I.&=4\B2U_M+P_X3
MT'1M0^S3%#-;_;-.L+:X\B4QQF2+S/+M
MZ9?Z1J5NLLL#3Z?J5K+97D(G@>.>$RVTTD8EADCEC+;XW1P&'\EG[37_ 16
M_P""RCP]J.EC55F%KJXOK6**%(E3IRE&4H0E*
M&L)2A"4H/O"4H2E!^<91?F=%+%XNA2K4*&+Q5"AB4HXFA1Q6)HT,3%*RCB*-
M'$TJ.(BDVE'$4:\4FTDDVC^GCXB_LS_LY_%_4#K'Q6^ OP;^)&LE(8O[:\
M#3P;XHUE8H %AC35]9T:\U%(XT'EHB7*J(B8L>6Q4S?#O]G#]GKX17BZC\*O
M@5\'_AMJ:QO%_:G@7X:^#O"FJ-'*I21)-2T/1K&^D$B$I)YEPV]3M;*\5_*O
M_P %<_V2_P!@3]ESXL?\$9?V'V@)\._P!AO1O''[;-Y\0-*U?QM\2;Z+3=
M)\20_ SQ'J5Q<>+HM_X)_\
M_!/S_@GS^U-\>/\ @BZ?#'B+QO\ $3X@?!OX'3ZPWBSXI>-]&TKXI>(M3N]'
M\&ZG=VGQ:U'4%2]\*>'_ !QXDU_3+.WB31-3U5],B\11ZA80/9UC]2P7MOK'
MU/!_6+\WUCZIA?;\W\WM_JWMN;^][7F_O'JOBCB=Y:LE?$W$CR94_9+)WQ%Q
M \H5+;V*RIYZ\L5&W_+E9;[%=**W/Z>+_P 1>']*O+33]4UW1]-O]0(%A8W^
MIV5G>7I:3RE%I;7$\=O#NGZM9:YJ,-EY-MJ^I:I&@B7X]_:
M4\=?L]_\$^/^"Q?_ 3AA^*7Q*?P)\$?@E_P3@UCX0:;XZ^(%U?ZWJ3V.@/X
M^\#^$F\1ZAHVDRW&IZ]JT>G6@U#4(=*MX;O499[DP6L@>$M T?4%@G 6:%;W3M/MKE8I@ )8Q*$D =2
M *[FOY@/VR/V^_V//VP_VS_^"17AO]FCX[>$_BYKG@[]MBRUSQ-IWAVU\0V\
MVD:3?^'186E[""."#P1P:^9/'O[)O[''B26
MY\3_ !*_9R_9RU2Y,BR7OB7Q;\*OAR]VTDC>6IO-O?#SX=>"/#MW<6UQ'M,L.L^'=(M+FX2XB.&F%U)YR'YG8&O,?"'_!/K]A7X
M?^,M%^(O@?\ 8\_9I\(^/O#>KQ>(/#_C3P]\%OA]I/BC1=>@E::'6M+URRT"
M'4;'589V:>+4+>XCNHYCYJ2K)\U?D]X)_9TTO_@DQ_P43_91^'O[-7B[QWI_
M[&?[>-[\8?ASXR_9X\5^*];\8^#_ (1_%[P-X&/C[P-XU^&-YXCN]0UFP?Q;
M+:7?A_6K74=4O+U[5M0GOM0UN)/#MEX8](_X(J_\E$_X+#?]IE:SI&NVOV[1-5T
MW6++S7A^V:5?6NH6OG1A3)%]HM)9HO-0.A>/?N4,I8 ,,_SM?$'X:ZK_ ,%;
M?^"EW[47[-7QR\6^+=-_86_X)^V/P>TO5_@9X*\3ZWX0L?VA?B[\5_#-UXL3
M5OB?JV@WVGZQ=:%X5;2=-_%_P ,OBS\)/'IU.VG
MUJ33O&NN^)]6TOQSX5U*QLCX8U'3-02WL[O4?MOV!XX=3L=!?%+X$?LO_M6
MZ7HEO\8_A1\%?VA-'\)7U]<>'H_'GA/P=\2]/\.:CJ4%M%J4FE?VQ9ZO!I=W
M?6]M9I>FV,,MS%;VPFWK%%M_%.^^#NK?\%@/VW?VN_ ?[1?CWQQI?[#?[#_Q
M(\.?!3PO^S?\//%.L>"M'^.7Q3&A_P!M^.O%WQHUO0[JSUW5M.T.Z>VL_#NE
M:7>:L:1XA^/G[.GP4^,^O:!ICZ-H>L_$_X:>$?'&IZ1I$MU)?2:
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ML]\/:+:^&] T/P[8RW,UEH&CZ9HMG->R+->2VNE64%C;RW-_^%I:;\)/
M]GX__P"$RUB[N[_5O%/_ EEOHL>M_\ "0:E>W][=WVK?;?MUU<7=Q--,\DT
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M&/@WPS\/O ?A>UDLO#?@WP;HFG>'/#.@V RVND:)I-O:Z=I]O)>75S=/
M#:V\2-<3S2E2\C,?//C5^S#^SE^TBGAN/]H+X$_"7XV1^#FU9_":?%/P!X8\
M=)X;?7AIJZVVAKXDTW41I;:NNC:2-1-F(3>#3;$7'F"UAV>Z44 <7\//AQX
M^$?@S0OAU\+?!7A?X=^ ?#$%Q:^'/!G@O0].\->&-"MKN]N=2N8-)T/2+>TT
M[3X;C4+V[O9H[6WB22ZNIYW!DE=F[2BB@#\^/VE?^"5'_!/7]KOQ/)XV^/\
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M^+=[9RPV_P#PL/XCZ9>_#SPY?R0-Y.H2/XO]8/CZ"RV1?8OA_P##WQ.W]JZ/-906MAJOBW3M*TK1WDT3PWKMC* ?
MU]_L3?LR^'/V.?V4_@9^S;X:CLVA^%W@'1]&UW4;*$0P^(?&UW&VK>/?%)3:
MKA_$WC+4-)+Y+?<4A7'U+110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^5_[5_PE^)?B_\ X*>?\$EOBIX8\$>(M<^'/P?L?V^H_BCXST[3Y;CP_P"!
M'^(?P,\$Z!X'7Q)?H/*TYO%.M6-YIFC"8C[9>6TT,>60U^J%% 'X$?\ !7GX
M8_$;6_VQ_P#@E/\ &_0OV9OBM^TU\*/@!XN_:?UGXS^&/A5\/=.^).H6>E^+
M?#WP;TWPS;7GA[6[_2]#N9-6O],U&>Q@U74;2"9-%OYHY#+:JC:/[1WPJ3_@
MI1^Q;^T-^SK\"OV2?CM^Q'\1] N?AY\6/A=K/QS^#'@KX(>%_%GQ0\&^)%U[
M0K/2[GP5XK\3)>WD]IH%SXTRUT?QE9? _X!P?%'X3>,?$5C;1VM
MWXC\'_$O2O%%CX0T[2-&TT_5?$MG9-JDOGOCOX&_%']H
M;_@K=^P1^TE\0_V8O$-E\(I?V"-?A^*6E^._#>F>+O#/PH^)_BR/QKXAC^&'
MC+49[.XT&7Q?X;O]/WWHH _$_P#;U_9*FOOVGO\
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M]3\3ZI::?]1?!W7_ -H#_@E!\!I_$.J_#>VU'4=3\*>'O"?AFXN;O15U
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M^)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MFN&G,QYE:9:6]AINFZ?90I;6=A86-K'%:V=G:6\<<%M:V\4<$
M$,:11(B*JB]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!
end
EX-101.SCH
4
biaf-20230324.xsd
XBRL SCHEMA FILE
00000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.DEF
5
biaf-20230324_def.xml
XBRL DEFINITION FILE
EX-101.LAB
6
biaf-20230324_lab.xml
XBRL LABEL FILE
Class of Stock [Axis]
Common Stock, par value $.007 per share
Tradeable Warrants to purchase Common Stock
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
EX-101.PRE
7
biaf-20230324_pre.xml
XBRL PRESENTATION FILE
XML
8
R1.htm
IDEA: XBRL DOCUMENT
v3.23.1
Cover
Mar. 24, 2023
Document Type
8-K
Amendment Flag
false
Document Period End Date
Mar. 24, 2023
Entity File Number
001-41463
Entity Registrant Name
BIOAFFINITY
TECHNOLOGIES, INC.
Entity Central Index Key
0001712762
Entity Tax Identification Number
46-5211056
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
22211
W Interstate 10
Entity Address, Address Line Two
Suite
1206
Entity Address, City or Town
San
Antonio
Entity Address, State or Province
TX
Entity Address, Postal Zip Code
78257
City Area Code
210
Local Phone Number
698-5334
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
Common Stock, par value $.007 per share
Title of 12(b) Security
Common
Stock, par value $.007 per share
Trading Symbol
BIAF
Security Exchange Name
NASDAQ
Tradeable Warrants to purchase Common Stock
Title of 12(b) Security
Tradeable
Warrants to purchase Common Stock
Trading Symbol
BIAFW
Security Exchange Name
NASDAQ
X
- Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition Address Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition Address Line 2 such as Street or Suite number
+ References
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
+ References
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition Code for the postal or zip code
+ References
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition Name of the state or province.
+ References
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition Indicate if registrant meets the emerging growth company criteria.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition Two-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition Local phone number for entity.
+ References
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition Title of a 12(b) registered security.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition Name of the Exchange on which a security is registered.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition Trading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue.007PerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=BIAF_TradeableWarrantsToPurchaseCommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
XML
9
form8-k_htm.xml
IDEA: XBRL DOCUMENT
0001712762
2023-03-24
2023-03-24
0001712762
BIAF:CommonStockParValue.007PerShareMember
2023-03-24
2023-03-24
0001712762
BIAF:TradeableWarrantsToPurchaseCommonStockMember
2023-03-24
2023-03-24
iso4217:USD
shares
iso4217:USD
shares
0001712762
false
8-K
2023-03-24
BIOAFFINITY TECHNOLOGIES, INC.
DE
001-41463
46-5211056
22211 W Interstate 10
Suite 1206
San Antonio
TX
78257
210
698-5334
false
false
false
false
true
Common Stock, par value $.007 per share
BIAF
NASDAQ
Tradeable Warrants to purchase Common Stock
BIAFW
NASDAQ
false
EXCEL
10
Financial_Report.xlsx
IDEA: XBRL DOCUMENT
begin 644 Financial_Report.xlsx
M4$L#!!0 ( "I >%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04
M " J0'A6%?G5_.X K @ $0 &1O8U!R;W!S+V-O&ULS9+!
M2L0P$(9?17)O)TEE#Z&;B^))07!!\1:2V=U@TX1DI-VWMZV[740?P&-F_GSS
M#4QKD[(QXW.."3-Y+#=CZ/JB;-JR(U%2 ,4>,9A23XE^:NYC#H:F9SY ,O;#
M'! DYQL(2,89,C #J[02F6Z=53:CH9C/>&=7?/K,W0)S%K##@#T5$+4 IN>)
MZ31V+5P!,XPPA_)=0+<2E^J?V*4#[)P3M3DC%A1*;]]GUA]]5.$3G]_X?
M&U\$=0N_[D)_ 5!+ P04 " J0'A6F5R<(Q & "<)P $P 'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%#BVR]*+
M41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI@S
M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (
M "I >%;YHG+"Z@0 (\4 8 >&PO=V]R:W-H965T&UL
MG9A=<^HV$(;O\RLTM--I9Y)@B\^DP PA< YS$D(#IVE[)VP!FMB6*\DA^?==
M&;!):M;DY"+X:U\_VEWMRNILI'K6:\X->0V#2'VL>,GTI8Q[!
MG:54(3-PJE95'2O._-0H#*K4<9K5D(FHTNNDUZ:JUY&)"43$IXKH) R9>KOA
M@=QT*VYE?^%1K-;&7JCV.C%;\1DWW^.I@K-JIN*+D$=:R(@HONQ6^N[U36S/1G[W8ICB7C /6,E&/R\\ $/ JL$'/_N1"O9.ZWA
MX?%>?90.'@:S8)H/9/ D?+/N5MH5XO,E2P+S*#=?^6Y #:OGR4"G_\EF^VS#
MJ1 OT4:&.V,@"$6T_66O.T<<&-3;1PSHSH"FW-L7I92WS+!>1\D-4?9I4+,'
MZ5!3:X 3D8W*S"BX*\#.] ;RA:M.U8"4O5#U=F8W6S-ZQ.R>J4M"Z^>$.K3V
MWKP*!!D&S3!HJE<[HG9%.+AY^^(; E'+(&JH2A\(_)1B%+!5
M$05NOV2!Y@A'/>.HG^:,*5="^F08^02"6^@77"D+4UF<&AE: Q4<1D:8-S(2
M 2>3)%P4YPZNX3CN1=VM-S&>9L;3/(7GD:^$-HJ!SR8L+'04KG,S?NB/1N/)
M>/[WV7PX^#IYN'OX,A[.SLEX,KA$0%L9:.L4T &$5;& C".?OY)O_*T(%5=R
MP'\ME[::%,%J9UCM4[#F[)6,?6 32^&QM%P>CRZN6&]>-*CK.HTF@G>5X5V=
M@C>./*EBJ5*R%7ZA3''Q6^'"*'KY 74.86Q[_N*:WV^
M/R!W\!QYB K!2B0I!0^>/<&X#54MPL5K_$>\+!>G2KZ(
MR"L.-ZXY_PM#R[N&BQ?[CVA3":D3D']$?'2"E"BVVK31PMCRMN'B-3^-8A^6
MC<=1< &*3X"\7[AXH;^3'OADNI81UL!*1)I7[8M&K5;'B/+&X.+U_$D)8W@$
MC@G#)-J57UU(A0N5+3_ V?R4!XPHAH1>XAO95@02$/KE+*DW=^@>+FW
MWN%L ;%]8LI^^FAB)(D3!80PEPX3MA 45?_1K,Q;#,6;PV>RLD1I[X4.B> ,Y(3-Q 9N93]B61=Z!:GBK.#TU2X2.IV;U8'O);M7=,]M+- GX
M$I2&!FG.TX+:8P,T\,UAR@I^P#<7TII]B=V$RO;@^S]!U!+
M P04 " J0'A6X/0ZB:H" P# #0 'AL+W-T>6QE&:.9N:,9F235>/.DC\>.7>D4U(W:WITKGZ?),WAR!5KWIB::X^4QBKFO&JK
MI*DM9T4#3DHFB]DL2Q03FFY6NE4[Y1IR,*UV:SJCR695&GVQI#08_%*F.#DQ
MN:9;)L7>BGXM4T*>@WD!AH.1QA+GJ? UG8.E>0[P/&C 2T(M/!;2!0*FCZ D-8@@3%(A_'2W$O@K[]J_"DEJ,/EI>BZ_6NG/)CT>=X=%;7\OQ!BDHK'FK_[82;%1O]R-%8\>RSP:0*:6R:O2?O1CS-.AEF\&OB;<9^L
M!!XK:_H5GE;RPH'L6R&=T(-V%$7!]8NI]^$=V_O'X4U\O[[@)6NE>YK -;W(
M7W@A6I5/JQY@7X95%_DSG.YY-CW3?"ZA"][Q8CNHMMKW(O&"SSI@*&<5M&D27JLT1]@E<,V?8?+$_<)_=7
MO-(\3],LPW9TNXTRV&+[EF7PC4?#N($'E@X]W&)^3U.6!>PV8'\\3PP4W&?-(6N8MRP$XPC>8XA,(OQ
M&%:7BKL-8?20$3;8T.P6BP^0"X9
M9K>]9!:G%
MC:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*
M0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,Z
ME._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8
M,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]
MC.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\
MGN4/4$L#!!0 ( "I >%8D'INBK0 /@! : >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*
MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L
MXEF&!KS2O6H0DBBZ0=@S9)[NF:*/Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5
M&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFN
MWPQP>'3^ 5!+ P04 " J0'A699!YDAD! #/ P $P %M#;VYT96YT
M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;
M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:
MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( "I >%8'04UB@0
M +$ 0 " 0 !D;V-0&UL4$L! A0#
M% @ *D!X5A7YU?SN *P( !$ ( !KP &1O8U!R
M;W!S+V-O&UL4$L! A0#% @ *D!X5IE&PO=V]R:W-H965T
M&UL4$L! A0#% @ *D!X5N#T.HFJ @ , P T
M ( !+0T 'AL+W-T>6QE&PO=V]R
M:V)O;VLN>&UL4$L! A0#% @ *D!X5B0>FZ*M ^ $ !H
M ( !2Q( 'AL+U]R96QS+W=O9(9 0 SP, !, ( !,!, %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4& D "0 ^ @ >A0
end
XML
11
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
12
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
13
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.23.1
html
3
24
1
false
2
0
false
3
false
false
R1.htm
00000001 - Document - Cover
Sheet
http://bioaffinitytech.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
form8-k.htm
biaf-20230324.xsd
biaf-20230324_def.xml
biaf-20230324_lab.xml
biaf-20230324_pre.xml
ex99-1.htm
http://xbrl.sec.gov/dei/2022
true
false
JSON
15
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"form8-k.htm": {
"axisCustom": 0,
"axisStandard": 1,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2022": 27
},
"contextCount": 3,
"dts": {
"definitionLink": {
"local": [
"biaf-20230324_def.xml"
]
},
"inline": {
"local": [
"form8-k.htm"
]
},
"labelLink": {
"local": [
"biaf-20230324_lab.xml"
]
},
"presentationLink": {
"local": [
"biaf-20230324_pre.xml"
]
},
"schema": {
"local": [
"biaf-20230324.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 65,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2022": 2,
"total": 2
},
"keyCustom": 0,
"keyStandard": 24,
"memberCustom": 2,
"memberStandard": 0,
"nsprefix": "BIAF",
"nsuri": "http://bioaffinitytech.com/20230324",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"b",
"span",
"p",
"body",
"html"
],
"baseRef": "form8-k.htm",
"contextRef": "From2023-03-24to2023-03-24",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "00000001 - Document - Cover",
"menuCat": "Cover",
"order": "1",
"role": "http://bioaffinitytech.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"b",
"span",
"p",
"body",
"html"
],
"baseRef": "form8-k.htm",
"contextRef": "From2023-03-24to2023-03-24",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 2,
"tag": {
"BIAF_CommonStockParValue.007PerShareMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, par value $.007 per share"
}
}
},
"localname": "CommonStockParValue.007PerShareMember",
"nsuri": "http://bioaffinitytech.com/20230324",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "domainItemType"
},
"BIAF_TradeableWarrantsToPurchaseCommonStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Tradeable Warrants to purchase Common Stock"
}
}
},
"localname": "TradeableWarrantsToPurchaseCommonStockMember",
"nsuri": "http://bioaffinitytech.com/20230324",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Description of changes contained within amended document.",
"label": "Amendment Description"
}
}
},
"localname": "AmendmentDescription",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "stringItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_AnnualInformationForm": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
"label": "Annual Information Form"
}
}
},
"localname": "AnnualInformationForm",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_AuditedAnnualFinancialStatements": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
"label": "Audited Annual Financial Statements"
}
}
},
"localname": "AuditedAnnualFinancialStatements",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CountryRegion": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Region code of country",
"label": "Country Region"
}
}
},
"localname": "CountryRegion",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page."
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentAccountingStandard": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
"label": "Document Accounting Standard"
}
}
},
"localname": "DocumentAccountingStandard",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "accountingStandardItemType"
},
"dei_DocumentAnnualReport": {
"auth_ref": [
"r11",
"r13",
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an annual report.",
"label": "Document Annual Report"
}
}
},
"localname": "DocumentAnnualReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentPeriodStartDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
"label": "Document Period Start Date"
}
}
},
"localname": "DocumentPeriodStartDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentRegistrationStatement": {
"auth_ref": [
"r0"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a registration statement.",
"label": "Document Registration Statement"
}
}
},
"localname": "DocumentRegistrationStatement",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentShellCompanyEventDate": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date of event requiring a shell company report.",
"label": "Document Shell Company Event Date"
}
}
},
"localname": "DocumentShellCompanyEventDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentShellCompanyReport": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
"label": "Document Shell Company Report"
}
}
},
"localname": "DocumentShellCompanyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "submissionTypeItemType"
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"auth_ref": [
"r3"
],
"lang": {
"en-us": {
"role": {
"documentation": "Documents incorporated by reference.",
"label": "Documents Incorporated by Reference [Text Block]"
}
}
},
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "textBlockItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine3": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 3 such as an Office Park",
"label": "Entity Address, Address Line Three"
}
}
},
"localname": "EntityAddressAddressLine3",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCountry": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "ISO 3166-1 alpha-2 country code.",
"label": "Entity Address, Country"
}
}
},
"localname": "EntityAddressCountry",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "countryCodeItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
"label": "Entity Bankruptcy Proceedings, Reporting Current"
}
}
},
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityExTransitionPeriod": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
"label": "Elected Not To Use the Extended Transition Period"
}
}
},
"localname": "EntityExTransitionPeriod",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r16"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityPrimarySicNumber": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
"label": "Entity Primary SIC Number"
}
}
},
"localname": "EntityPrimarySicNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "sicNumberItemType"
},
"dei_EntityPublicFloat": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
"label": "Entity Public Float"
}
}
},
"localname": "EntityPublicFloat",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "monetaryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "employerIdItemType"
},
"dei_EntityVoluntaryFilers": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
"label": "Entity Voluntary Filers"
}
}
},
"localname": "EntityVoluntaryFilers",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityWellKnownSeasonedIssuer": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
"label": "Entity Well-known Seasoned Issuer"
}
}
},
"localname": "EntityWellKnownSeasonedIssuer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_Extension": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Extension number for local phone number.",
"label": "Extension"
}
}
},
"localname": "Extension",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_NoTradingSymbolFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a security having no trading symbol.",
"label": "No Trading Symbol Flag"
}
}
},
"localname": "NoTradingSymbolFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "trueItemType"
},
"dei_OtherReportingStandardItemNumber": {
"auth_ref": [
"r13"
],
"lang": {
"en-us": {
"role": {
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
"label": "Other Reporting Standard Item Number"
}
}
},
"localname": "OtherReportingStandardItemNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "otherReportingStandardItemNumberItemType"
},
"dei_PreCommencementIssuerTenderOffer": {
"auth_ref": [
"r7"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
"label": "Pre-commencement Issuer Tender Offer"
}
}
},
"localname": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_PreCommencementTenderOffer": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
"label": "Pre-commencement Tender Offer"
}
}
},
"localname": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r1"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_Security12gTitle": {
"auth_ref": [
"r5"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(g) registered security.",
"label": "Title of 12(g) Security"
}
}
},
"localname": "Security12gTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r4"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_SecurityReportingObligation": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
"label": "Security Reporting Obligation"
}
}
},
"localname": "SecurityReportingObligation",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "securityReportingObligationItemType"
},
"dei_SolicitingMaterial": {
"auth_ref": [
"r10"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
"label": "Soliciting Material"
}
}
},
"localname": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "tradingSymbolItemType"
},
"dei_WrittenCommunications": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
"label": "Written Communications"
}
}
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [],
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "domainItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://bioaffinitytech.com/role/Cover"
],
"xbrltype": "stringItemType"
}
},
"unitCount": 3
}
},
"std_ref": {
"r0": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r1": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r10": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14a",
"Subsection": "12",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r11": {
"Name": "Form 10-K",
"Number": "249",
"Publisher": "SEC",
"Section": "310",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r12": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r13": {
"Name": "Form 20-F",
"Number": "249",
"Publisher": "SEC",
"Section": "220",
"Subsection": "f",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r14": {
"Name": "Form 40-F",
"Number": "249",
"Publisher": "SEC",
"Section": "240",
"Subsection": "f",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r15": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r16": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r17": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "405",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r18": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "425",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r19": {
"Name": "Securities Act",
"Number": "7A",
"Publisher": "SEC",
"Section": "B",
"Subsection": "2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r2": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r3": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-23",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r4": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r5": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "g",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r6": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12, 13, 15d",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r7": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "13e",
"Subsection": "4c",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r8": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14d",
"Subsection": "2b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r9": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "15",
"Subsection": "d",
"role": "http://www.xbrl.org/2003/role/presentationRef"
}
},
"version": "2.2"
}
ZIP
16
0001493152-23-008779-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001493152-23-008779-xbrl.zip
M4$L#!!0 ( "I >%;U0AE#^0, + 1 8FEA9BTR,#(S,#,R-"YX
MQO;U
M^&8XM,B[MW_]2?#I_FW;9, @"CJD+WQ[R$/QAGRB,73(!^ @J1;R#?E"H]3,
MB &+0)(;$2<1:,"%W%*'7-3J5Y38]@FZ7X '0C[<#Y>Z,ZT3U7&<^7Q>X^*%
MSH5\4C5?Q*<)CC75J5JJN0NW>$ZCWS'E+\GMUEVB+A?W[.L4^%7:IWRN'FFK
M_]$;M?^]^';5@J?9R^/[A>?%K?ZKGTPN6?-Z/+C_IL7C0RCZN9>(KPILW:T).G8;KUIVO=[?C#&?EP,XB8OQI'[S>;K>=;+6$[B 7GHQ*
MZ:9CECVJ8*F,J^P(GG&E*?$M;!%TZ^N %E>Z&M',I*: !;. 5^;2I>
M'%Q ?*-1 E-E3RE-EN"0*B\355+;*DTR\'.SA./L7NB&IJ'JUP34?M5L:8,0
M:+E%V-@W7';,LN&XMENW&_62^7YX/5B2/"9H+.]*L&?V;2VE":;K/Q#Q[.
M"&+@>B!DW(>0IA%&\IS2B(4, HMH*J>@39ZJA/IPFFB9\Y1S@4<#SVV.7*I"1.'&:7K;(/7)%(%P6?^-ALG$A3RLB!N<:(@%I #))]&?AI5XZQ<
MV4LI)LK-6FU?>=#N(239 >V8G.A9BIDKTBKF9A+"GN4Q&MKE5_J.H=4P74J(
MD3YR0+.=W]Z-PG I0:6_H[)S@:"(2$!JAMF^=DODKC-MZ*,U,\38419Q?D7(
M$?6JAHP4B'YCK+=&_Y<&B9E4-;*;O>L)OUVD(%*T^K.+':AFI.E+PSG#A0
MT_;95X?@9F"2J7&JT645*XKF*4;WH&J^5!_A%,*IQK]HPLV#5^, 6*_C'KQDS;^1W_S6+!QUKX3R,J
ML[^:FNM>CD".9U3"'<2>Z=Z,SZ9_.PW,(JS#IHAHF9JZ8OXF.EAOF @F65D,
M4IE%A!UK_E[VSIU Q)3QH8;8('$'4D]A14H-^H,4*3;YN1Q#R+' )I(&8+QX
MI%)2KM5$C%+IS_"J7@MC,[Z*G/\WS*Z39P,._P-02P,$% @ *D!X5K]K
MVW,$"0 DF@ !4 !B:6%F+3(P,C,P,S(T7V1E9BYX;6S575U3XS@6?=^J
M_0_>['/(5S,SS30[%=)D*C7=#4N8[MU]H11;250H$B7)D/S[E?P1[%C7=A@0
M-@^0./=*YYXC7^O:4OCTVW9#O4$+8Z[_PY[X[GD]FL
MXTF%6( H9_B\PWCGMW_]_6^>_OGTCV[7FQ),@S/O,_>[,[;DOWK?T :?>;]C
MA@527/SJ?4MU(,\Z_6>GIY.&']$3US;24Y[YA^DVZ?1B=H2YCAS<>=U,NT8O,;
M?/SXL1=]FIH6++<+0=,^1KT4SKYE_6F@]@Y9X]->_&'6E)0TG0$MR9F,(OG"
M?:2B$5*)R ,MS+MN:M8UA[J#87.F9OUKH?:\+PM%R
M21A1.X7]M9&X9VQZ$ZZ'L 8<>:\%7IYW%@0M=2?#47\T_&"Z^&?.2.T>]%"6
MQ(S$CM?+=8^$GR*P&6=[ 8)-.3=1GD:=KW43P@\7N!N0#69FU'>\I*-LB/M6
M"%,];=I+;'K6!MX>][ZS;L WB!P)NNCM ''44W>#-PLC]U%P\ZYOCQ51>AS"
MR.'M<3&NQL="2WVLSYL^^+
M^A8MG@=4">+$[A#ML^9CD>).!DS-LS(>I6<^9TJ/DDL:]:9'.EZ9%RFRI>";
M2BH3VGAI!%EN-9".QT6 A9[#]9^Q4"YQ<-Y1(K2$[%B@"4527BWGBOOWXRVI
M,[J*+J\JF_626B53GGU (BA6BUKOI4L6XN?DX@P)8K-]526*\X0J&4"&>25R
M2(IAOYU:W TLP%]+CO0*^5>SVXOUBJ*#)!N]5+)B=7 Q&T_O=&6ZX2SJ_1J)
MJ" \Z?=_OL9BOD8"?TTFA@5MC',MWS?0*C]G!70H.0_X2T( T]E+\QD@R*U
M 389]P<2 C$E;_EU*/RUKB S8$MU.::).UL.:(P\1T<"9KI7N>I([)^L^&,O
MP"1.VM;M&BCC;)6MQ]>!_RJV=@-J 0MZ]R$:FF=JS!! ;0
ME**5G=N<2:/)+2)]T^G2$>Q^QM(7Y$%EIH8 R1G+=G!]"!A,%FYSQ0U>$:E$
M=+MQ'U!Y\K"Z-%J$:N3@C,>M&F/&0D1O\ ,7%2)D+5O!?0$P1/D'MY3_.T1"
M84%W=5@_,&X%\3;,$/>GCBEHE(ZKJD']HW0KVK: A^G]R2_]\C2DU3P<1
MJS7ZB_:MD " #8GP\_N).:3&+V[5T+4WX8&.2=30
MX<"X%0K8,$/&6S 02VJF:G-OOV\%^$#:K@J&I.1H2YC0(MN\J9
M-)KK(E*07D>EL;GFC 5&\+#.6C2;W$.@(+>.ZMPOW#S567-6>@_YT*K1'%O!
M@CR[*E?-/CP)IH?]QXUF-H\2HO3%>QR.I/2'($KC,2O)0Y;<00*>_%E-&TTU
MC!BDW5').>>4^)HAMOJJXQ $43OG1;M&$P[ !=EV5%U>BVBK!-:3_&@QG-G,
M*ZZ62RA3P_:-9K\"-JB"HS+S -Y,RA"+8[4H>+5)$3MX4!=')><<^Z%.E+O!
M<'%K=JD#F>C JM&\6\&"/#LJ,[]QLY5+Y\;Y;K/@%-["8S%L--L07I!P1Q5E
M#I6=ZIQ)HTDN(@7I=511IB?9Y=9?([;"\(H.FV6CR08!@YP[JC2?$]NJ5JY>
MM2E7KVKD:D>59@HJ7JBOS[NK!24K!.\(+'%H!?L0;D@(6TQO(42\7\M\<9O8
M1*BF^H5= JMIH\F'$8.TN]H*&P9$X2 &."4,,5\7<_N@@#L$55[-%J,.>% 7
MI\])?V!*_V#\BGWSD-F4(B6G(K@'/#
M:MH"^FV(0=J=/B1-EI7OKUSQ-WJ6L6_W:($()P>+="B!#BHA=.%Q]&).M'QK'CYVH&<80N8+^(%"7>ZWGB^091>A%('
M($OS3\ZP!807\8*$.UU1?+G!8J73X.^"/ZEULI&WC'BK0PL$@'CA=.7RY
M??YB@7A78ZD*!>LV2& '#?%_ZGC;[-CWS5*3>$[ B0 !6#[1FM0 1M4P5&9
M?*766&1G91$T$TS90I JKT8K4@L\J(O3,CG[-0^EE^6,7:.Y!^"";#NM@J_#
M!27^E')4.N_/F+6 ZT.T(-5.*]\+Q.Y%^*#\W;7@/L;FP9#KRJM01?]D1:,MO7%1XM<"F2KA@^HX_BHJ^;QE#P<7
MNQN\Q,(LWKC%6W6A.[HOGUQ5NC=:J^.B "7+E-Z?>@3_4$L#!!0 ( "I >%8)46E(\PL V0 5 8FEA9BTR,#(S,#,R
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M\>5H?')R.OKW^YMIL")K/(RH/&\!&111LA13W.FK5Z]&:F\A;2AWJ$5?<9)$YXFR=\,"G*IF[SP, A7RMV$A&\I-P]/Q\.ST>)>$@^+D
MJS/(64P^D 52U3Q/GS<"I222) SR;2M.%F8S,>$[B 9)*P0=8KU>ULO*@D6VS]X1'++RB+W.M1SNR+_YV>/H-%:C&
M6Z_"C*4X?I'Y:J1UV[?D96=\'V?_3(M^GKSL3%ELZ!6;BQ[<\:;=9X6TY0%#Q>[*"F.HRKY
M9M!#/](K(",O>%$+S(..4Y$K1@$3 ]DF'<;92<_"%YRM>]G(SQGK(?X:S\OR
MLY,L+ 5J"$!.3LY&_]-0?)V@OL@2T$9/Z
M1);Q.S$VXS@D>!Z3SYAS3--DQN[%:5F)*6>E4C!JA\5;(^XEU2K!.R38#_Y>
MX%C'L"P"%66@E*%-7@JJ4OJM*'Z_H7,F#7?U[+G(R2!9,V@<&97".46MMG14
M2A'ZHF3?//Y]/R#$G)!,Q,?.251%Z 2,AE$C'*7*/T!T:RV02"E2VN]+2D*"
MXR5['(4DRB 1'_9LB%^^OF/!5M$L2M0JU-QM@P/(E&Q]?9_S-@<,Z2U=2)#4
M6&[@"W'@4![\.L9+@WUMOZTF-MHJVKBVTXM&-CG26[G4("ERU+:A JHQQQ=$'I%L$Q\^=4#24MKD K.IH:#*OZ#![ P$IY6X9F7%,DTAV8)V0
M-*76+S< LXU+#TWG%2> .?B2I-2[)66Z(G$L'\[ M+M#,8EMTP(;UGEI*KTB
M!K0',J,B4![B#S97CW)V+J9)/2M;T;N$IV&[C9]2["U"NL.>%*DP).,85,69O("N9'"F]>TBN:-@+D5+G!A#-IAF/7.0A''5G
M76@(M4LPKJ,DP''FY5ILT[]>Z=#:!@2TJT/2$'H%"N0.A"4+*)A1(4Z!^0_!
MO!\N%:4;6!I6S:B4,@]!T;UU82+U3B"YW')>C5T=ID ;-:AT$0>46%V!F"1BY%2(R%W L8]C]:8/T^CH&.H: KMH@$9
MK;.AJSR" [ &T)&KT71RZ7(DF>'=)!2@1HLH6YS700FHMPM+A^TZ,X#8(W3:
M'0($B2!4CW()TH0&C&]8Y7&'2[85'>#S)0OA&4I'E%VH>E6ACE9KB$> ]?$)
M8%8+/24%,+JI6!2!9@A/B+L)0G*@D_^\FHN04K+]1:Y>N%KMUI@Q"CTB"
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M9I:,ZDB&E+A7&T;Q/;@J+;< $'K/0"DDY[.BPB8!A4(E 6@E2,6VPF2;(E
M_"!X#"&.$ +- R U]#[B!)GLA"H+=,G6E 1;,3X^GX[GLRAM)*$S2ZR-28"Y
M,*EL0
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M^D,S@-@+G/HX!!Z=D4'#!QF%BK#\3I@3DCZQ>$M3S-5:7EVJVFM57;1JU'S+0:A-9P
MYSD_]G/C+,K1$LN4P/K"\EM+ZIL,ZVOIC1I/4*HU2"X?K*,
MD:EB<,&4LY0Q_%),M9:LY2EQ364_<4S#8C-W3"GQ" ^3KY8,,AP56B%J3?A2#&^_"85Z]CE,FY+OTP-4.
MW2&V".IKON"H2^\%33U-ZDRIL/K%M0I4[T5TFGN+51)9GQ@:#VL2X
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M^#''"1%;_@]02P,$% @ *D!X5E7]5S--" +&, !4 !B:6%F+3(P
M,C,P,S(T7W!R92YX;6S5G5USXC84AN\[T__@TFO"1_JQR2;M)&S88;J[24-V
MM^W-CK %:"(D1I(3^/>5#": +?FP;3GN7F2).9+.^QQ9UK$EY^+7Q8Q'3U1I
M)L5EHW/2;D14Q#)A8G+9^#AL7@U[@T$CTH:(A' IZ&5#R,:OOWS[363_77S7
M;$9]1GER'KV1<7,@QO)U](',Z'GTE@JJB)'J=?2)\-0=D7W&J8IZI'O5)+&>P
M"H>&F%1O:FLOVNM_J^(7G(G'<_=C1#2-+"^ASQ>:739$IGI,F$XQ;31E[*U5)6KG-V=M;*OLU-"Y:+D>)Y&Z>MW)U-S?9;
M%K#?\D2SSTE-%QY>-$2-CVTCWM'W:
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M<&J5O:>ST Q"M8KVW[B?.AS,BGGNF<"!-M!)5LJ"POM&ZICQ>8.4 7A'4OL
M4?TPT"4BD4:(>SIA+C-QKFPTA(<,3Q'LP?N@020H&RD45T*DA-_3N505$=BU
M!(+_H1;@RT0B\?X])A*TBP#B\JET<
M"K*10F&S:283*T,!@E P!N(_JP5^CU14\#+#:E$ =ZS#BO"!R*AB]_H,D2\8 I%CIN]!G6B,+]3;$;43X+!?41 :%]Q,]@ &*-&Y2A++3:__'?
M/8Q_%\X?-\.MU%L3_J>'\3^%\\?-QZ?>XVA['&SW JM
MF.0S_V_5G9)/;+5PO@I_H00T!G5(?L.J44^!U8P TO]S2RCX.B3"Y2HQ@=])
M;0C_B\VK)J+E]E#X=4B)0XJ/?7MSU0'1'?6JD]$RAHW"RX5->QV;I0*TK\
M'7K7 DH6-[4M4W5DL.^D>R@SE2)X6[AH!06,FZ/ZU!U[<':;T[1W5-CZ&KQH
M#W?HW==S9)Z?%3/6 [>Z.Q7K^T&>!W@>4RAGW,0RJ//(S(>2LY@9)B;OK>>*
M$5X.O,P.2ALWC?0K/#+J.Y5M7*!V^IZM6',;6]7M>.P;G4/V4/2X662U8MP0
M#+1.J3HT$"6EH.' 32BAZH\]!-$XM2/BLM,=/;B]VIX!J& %A8Z;3/K4'1GR
M!^GV4]E!<+BR90PK@Y8ZDNI.'B9A%/
MB9A0_V*,@,;GR8'C,VXNZ5.'!'FU=MZ>8[&P#5I:"10-ZK"E2/\MSA,^7\-R&?Q9 2+05-5BE#Z-MP@T
M''5X[EFA&R46GR1/+2Z5K895GK/"8PIE7X?GG1Z=. M05VN]-]>GU0OI0NA]
M): 1J,.#S[!JI"5YAKK7>K$G^H88LO8P% A?"6@@ZO 0-*P:;:.!ZED%$QE^
M\K]G",5>AX7!I1I1: ]GA//K5%N7=7#8V3.$TJ[#"N!2C2BT;V943>QX]U;)
M9S-=[Z$-4?<4@-*OPSK?H&:<*"Q>MO*O=A4&0U!B#7YE1!WX>]5BO1TECMVZ
MD-5E7R1$>?"'[*$!J,<&5K_B(X?@UDRIVIYU9-<
MB+?>JA"\#N_80<'7(>4M4XBS 2T=<1;WN23!^?V.&11T'?+;$GTHG*^)>%3I
MW,3+.R5C2MUS';TY_P 9%K ":&SJD/D>Q 3GCL3+FR^S%Y3JV]1D?P+ ^A>\
M+Q$L!XU1'9)B" &DN9-^V35'D^OE/1U3Y19;/-"%N;8-/8:G4H#BT$#5XYU0
M8!XE\;IH%03:)A_MM^MOW _WIPWLD;\!4$L#!!0 ( "I >%:[?7[Q?@@
M /PS * 97@Y.2TQ+FAT;>U;;6\B.1+^CL1_J&-TT8P$!)BW#3#1DI#L
M<&*2;,+<:C^=3+>A/3%VC^T.87_]/=4->8]6LY?LD)M$2@ANN_S4>[D,W8^C
M3\/M;BX?=W<.^[_3R>CWX=Z'RL2:T*9F
M(PTT4C/IZ4#.Z=C.A*D6 U4ZD4Y-*EB(I4??NJY#,^&FRK2)IS8JV]W]PX/1
M52JUB9@IO6C_&9U\KE=_R&);4-K9WC!CGW:ZFSO@D^GBY>AA@'8HR/-0$UI-
M,>34- D/C'WO/%%C%%B\QRLZD9;"M6EL0\)&L53!X-,O='*\
M^Z$BS[>V:LW_-!K-^I=T6J'>2A4EDM3B1+DJENI><=FJLX)&UZ][Z1GE=N
M"F#M1/"WF5LD39#N@<&/E>U-)LJHL"B71C)*C-5VJD F6#J6J76!]FWF0D*_
M9L(! +4:K18T#Q;WE1$F4D)CIL]T\&0-?1(N2NAUL\H37Z^[":^4]\04-]C>
MM68BG321+)=VA=;DHT3&F98Q*Z&7.J7I=:*HE 6R3JLSKM"0\LA@(VZ&X.
M?GC=?,E\4)/% WO52>^@7.H=C X/!H>8+\^%IY>%8[3>%$IY11LF%C[I4/?S
M52^DJT[8W?R\7:6!B>KT\J!WTN_]VJ:=06^_D__][15[%QPU%@L2QM@,UA"3
M"HB@, B7>V^Y-+GP4K?TTHEU%!*)7RRPK/%?$^+X1GK:3%<*!1 BFJA/WJVE.]J*2@F"BS[*##7TV::
MM9_>OZ^UWC=JK>:;GY[MY7O:RX#/QT9PP2[TNIK+FV:KMM5HU=Z];3:>S>5[
MFLMOAH+3_!)? 4>N62DZD6"[*3
MO"DA^?Q4-"#&DL294%J,M%SG)UD1C;,UFE>:*BA")A
M2&AOF<3$9B8F9?(E W,F?0"I8ZGSV.7)RXC_*9< X,H):-[%JR!Y
M4]C)?#ZO*U?'1+&<&'"(JD=VQ@;S!#L7ZX00<:(WMAF\\+[F6M%8>VY0/XHO
MWGNOL&QGBCAVTGN^9X K&2GCW"N--35ESH179Y)B):;&>N79GZ5P>E'S04RY
M=6@BZ?)^7ZR\%$QFZ?(Z,]/\00"[,H#L"[;DQ>N.5$.[I\Z
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MX:U6,3BY[(E?[8'?[)$O][BWN7VC"7X[9UQ6\'?4Y==CII:3?,5%L7F%]*7
M5L7>JM#K;D(6=XAEC.AT6AM+& W0I+DLEZ+"SKF<+HE>(7%% 9NL@4+H:V8]
MCWI'_L! X+:T-I3!"X$QR""Y+SAUQW]$ZT41HGRY5+*U0 YY!UD@B;B/#1Z@V
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MLU9KU^ QQ;^P 1!!UE%G#)ZU!!CN%11L&"G+(U%*![<2Y0M<9-@Y77X3]^9[#U3HC?Q+>-_S8*Y=N-SS7
MW?=&RH4$X:+.[0ZIUQDJ##APH:I_UHE0/Z[A/O9'9U^42R_HQ5-#_1<:,*T.
M'::YE[9IR%<;S_V8/^G'/(EFRMU>M\G?WBF^SL/?^ODO4$L#!!0 ( "I
M>%8.CW_MS!, &*@ + 9F]R;3@M:RYH=&WM'6U3(CWRNU7^AQQWSY5;
MSP+#\*;H<@4(RJJ @*ON%RO,!(@,,S 3$/SUU\G, .#+_N "R[W7*TZ23K=
MG4ZGTYUT3OXWZFIH2$R+&OJW0"0D!1#1%4.E>NM;8,":P _]+[>R=M!O6@
MKFY]"[09ZZ7"X:>GI]!3-&28K7#DZ.@H/.)U G:EU,BWGBQ)D?#=U65-:9,N
M#E+=8EA7R*211O7.@D-QEJY?3ZLR__K1JF)E8MYJ&V<4,
MQI!#B@$L#(Z74E[@->CU--(E.EO:
MCM<1;?M1M[5ELA=;.N5SK0">:6C$\NU)E'A05)D99.,>L?S)A^(P+^9MI* 4
M"2MEBIC"IU: &;C:I3MF8$:4=4HPNKQR5
MHG(L(#0"P2K\1/Q_)XPRC:1/PO9/*.T2AA$'%23] 1U^"^0,G0$K@W6@*( 4
M^Z]O 49&+&PKCC!O%W; GOPK&$0%2C0UA6J$':,2[I(4&JFC8U0\%;\\2'+V
MX:;VEWQZELE4X >G!06#;VT=S3QPBA]\*'UP*7T'N)@\:?4KS>/1!P(S \B
M_^=U8.0X!QPRL5;453*Z(.,'";1G,B(G$^^A,GXT S<#TJQRB2YHN/70Q)I%
MW@$JP=E]^A!Y<)2:#1,^O0>&_%!K8Y-8#_*#T.$V$$M\>P^<4XY+Q8$574!I
M*?"&H8Z1Q<8:^19H@A2F4$3J,52G7:A2(D^H:G2Q_M7^\!40,&E3R+M*AVX[
ME5H]#8]32#=T(@KI*,4%EYA\1HB_J*H27JH2M"4[[2$$A/Q>$D[.EB-;UZ9"60%L+BVU'80R[O
M%W0V,<&,()9=@R\-*4NL^8 $@MYJBWT?H/B9M"=+J&1I0:<8J[YO@4LV@4=
M;.L&IRLO<+L[RQB8;F]038Q]RB$94?5%DET=YC8C@MN3KY/O5.4E34I,)$@A
MO@MJKGCA'9GYQM/NPK[].;WU@+^&NH@%6#4F.\6,I*AI5*+-Q12KH"=VVGAUS(E5CP%#>/J=ARRHW
M!;F9$;4":;[@I-[$A).P;W^SN(;]D?TC!:MN@O;%#8W<8A,,66;5C0KHA#88
MI#/L_C/DZSV\V(E9:@"6GY Q,!L61*-+L#4P2=JQ+U)0QP7F%GF[X-"6P+>-
ME:5=.$P0E7ZYCZE1M- / @DXN\Y6W%@HZ982Z*Y#MX,(^C']293D^);G2I
M_EJWK_-EOE\_P&ZYAPL+#'4LC!E[PC9O7-ON) SMX2?_[Z3W7COR&'6QV:)Z
M"O&JTC'BPAC$&FW!)P4F$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M8*"FP7=%G/F0 N+O'E95]^]W4S'C/IAX!11#TW#/ H3V%W7%,$'9BE,8PM.;L^/Y.4-=,OE-
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M_YC4!K5.DYFEH=5ABF7<,@8-"@&9T9.C66C,)7-$]0P8\@81F7S8II#,&47.)\
MN3T<7VEF]? P_NM1TG<[7_P1#*3K9(2M)40OT!SSH[EB0.?:3]I[P=VDY)NW
MB<)EX7[ET\G3>R"=/)3CR4\XDYQ_#Y;Y:K@X9TR"EX^!=#MZ_'&8K]P/?STL
M-AV#V?Y@95FZC+C6B'.J8&G@O^YKHQ7DK4]1_]-45T##?9R"=
M.#H,QJ,\M+M$@+P_/D:SP2]0'M80V1$
ME &C0Q[/ $,30&)=1=,0SW__?2A'DL<6H*>1'FDN$VVOY#!+PS T@G5Q-6]V+?1%B?/Y*!F+';^V'OXS_J]YBCJD
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MSQ'HH*TK)[9K2XK[
MW&R<7FB,H@/.N>2Q<&])<1$.8FTJ;JOT^&T5?MK3%BRY$93?>$UR I4+V;3=
M#-C0GQ<:6B6&>4<$]O?F9&!>H><]T7NWV9EHE+/;^.OR^VN6;_TLG]6N?SU\
M[Z/+F3D@BW%]7[P<+9YX58MOX/C\B2&BN;PN#?^\+K_6HPUT0FI,6OM=B#I/
M4>J<=^?W7!688SR/UHILAU<(7/]=CS<8I!\XH)'#]0^HB=6)-[(V[C8,[<#Z
MLAO.=0QG=/W#R2\;>Z-P6@3"M#7-GAP$V('EZ88?' 2+@:#;\IB^?!\:C;S1C.A/B??8V[\:N;0
MV?C+',6!M W"T1,>VFFCW6(<8XV;[[?1G[TVX\?(<;SI]WY\KYXT-V/(]PXL%3<7W;"772-
MKK#9(0Q=7N9\YL#.1EA4HO+:;(3W9")^>+X9WXP[I]W:<_T]!\+_82[H%RV&
M"21[C%UXW"?;SLEO)$D+,NXLF*KX7W2WB\/OYOE6N>L_)XK'*N3
M=A\;XG8GOQM)PBM&1&&M1L3[I+J<+7T_*S4'8_V?;??>)]4;8E+\N5>RUQ%!
M:_)K*,MB8OQ:DAUA0]X &UVXT@(R@XA&%$94I!LBH#J =9O7 @J/P^A !299$@M:-BD.M85?OP1*^+A+8XJ?WI.
MQ:9JV5=F> >SX=QIEM(#/,E/.AMM"RU,\80WVC.J3_"U4U7ZAWINVD8Q8M7[
MI/'KB7K>$K9?AM6;P_5;$^A9)\CY/6-WU^K+